Risultati per: Helicobacter Pylori: algoritmo terapeutico di eradicazione

Your recent ‘Chinese Consensus Report on Family-based Helicobacter pylori infection Control and management (2021 Edition)’1 and ‘Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention’2 will encourage more doctors in China to consider Helicobacter pylori as a curable aetiology for gastrointestinal symptoms, and as a smart way to prevent gastric cancer in the ageing population. The paper is based on results of a very large new study of H. pylori prevalence in China whereby investigators completed a China-wide breath-test survey of 10 735 families. Unfortunately, 70% of families had at least one positive family member although younger, educated and Eastern-China families had less, with 28% of persons being infected but only 20% of children being infected. In contrast, some North-Western provinces had 85% of families infected and 19% had all family members infected. The parents…

We read the Maastricht VI/Florence consensus report published in GUT with great interest.1 The report suggested that vonoprazan-based therapy is superior, or not inferior, to conventional proton pump inhibitor (PPI)-based triple therapies for Helicobacter pylori eradication.1 However, the number of randomised controlled trials (RCTs) was small and the majority of previous trials were conducted in Japan.2–5 Recently, several new RCTs from other populations have been reported.6–8 Therefore, we conducted an updated systematic review and meta-analysis of RCTs to compare the efficacy and tolerability of vonoprazan and PPI-based therapies for H. pylori eradication. Detailed methods of the inclusion and exclusion criteria, systematic review, and statistical methods were shown in , and the registration number is CRD42023394825. Of the 489 articles identified, 476 articles were excluded (). A total of 13 RCTs were…

Helicobacter pylori infection is associated with a decreased risk of esophageal adenocarcinoma, and the declining prevalence of such infection might contribute to the rising incidence of this tumor. We examined the hypothesis that eradication treatment of Helicobacter pylori increases the risk of esophageal adenocarcinoma.

Gravina: ‘Una medicina del sonno sempre più personalizzata’

We appreciate the considerations of Hsu et al about the recommendation of empiric first-line therapies in our Maastricht VI/Florence consensus report for the management of Helicobacter pylori.1 2 We fully agree that H. pylori eradication therapy should aim at a cure rate of ≥90%. This also meets the expectation of patients as referred by the authors from a real-world expectation survey of the Asia-Pacific region.3 However, we disagree that the cut-off for clarithromycin resistance, at least for now, is too high at 15% for triple therapy consisting of proton pump inhibitor (PPI), amoxicillin and clarithromycin used as empirical first-line option.2 Hsu et al suggest a cutoff for clarithromycin resistance at or below 5 % for the empirical use of PPI-amoxicillin-clarithromycin and base their claim on a recent systematic review.4 However, this review has several relevant limitations: First, the…

We read with utmost interest the study by Zhou et al,1 which was the first family-based investigation of Helicobacter pylori (Hp) infection in China. The authors provided valuable insights into the occurrence of familial cluster effect on Hp infection and the superiority of the ‘family-based strategy’. However, their work failed to compare the screening efficiency of various established Hp management methods, leaving us curious about whether the ‘family-based strategy’ could identify more Hp-infected participants with equal number of tests conducted as compared with the widely used ‘test and treat strategy’.2 Fortunately, the family-unit data in Zhou’s study offers the possibility for such exploration. To address this gap, we built a database consisting of over one million households, based on the infection status of households and individuals from 29 provinces reported by Zhou, in order to simulate real-world scenarios. The screening protocols were simulated in national…

È pronto lo strumento che calcola in base a posti letto e tipologia di pazienti il il personale necessario a ogni ospedale. L’obiettivo è sostituire l’attuale vincolo sulle assunzioni

Studio tra Trieste e Londra pubblicato su Nature Communications

Studio tra Trieste e Londra pubblicato su Nature Communications

We read the Maastricht VI/Florence consensus report for the management of Helicobacter pylori (H. pylori) infection by Malfertheiner et al1 published in the Gut with great interest. The experts addressed that the goal of any antimicrobial therapy is to cure reliably H. pylori infection in the majority (eg, ≥90%) of patients. The goal of cure rate ≥90% meets the expectation of patients in the real-world expectation survey of Asia-Pacific patients for H. pylori eradication therapy,2 which showed 91% of accepted minimal eradication rate expected by H. pylori-infected patients. In the consensus report, clarithromycin triple therapy is recommended as first-line empirical treatment in areas of low clarithromycin resistance, and low clarithromycin resistance is defined as clarithromycin resistance rate